UPDATE: Bank of America Initiates Repros Therapeutics with Buy on Androxal Potential
July 02, 2013 at 10:59 AM EDT
In a report published Tuesday, Bank of America analyst Steve Byrne initiated coverage on Repros Therapeutics (NASDAQ: RPRX ) with a Buy rating and $25.00 price target. In the report, Bank of America noted, “We are initiating on Repros Therapeutics (RPRX) with a Buy rating and $25 PO. Repros is
